Surface absorption in KCI and CaF(2) at 2.8 microm and 3.8 microm.

J. Harrington

DOI: https://doi.org/10.1364/AO.18.002534

IF: 1.9

1979-08-01

Applied Optics

Abstract:

What problem does this paper attempt to address?

Asthma and pregnancy: A review of management strategies with an emphasis on medication safety and outcomes

T. Conte,C. Bergeron,J. M. FitzGerald

DOI: https://doi.org/10.1080/24745332.2017.1409090

2018-04-09

Canadian Journal of Respiratory, Critical Care, and Sleep Medicine

Abstract:INTRODUCTION: Globally the prevalence of asthma during pregnancy is increasing and asthma brings a greater risk of maternal and perinatal complications including: pre-term delivery, low birth weight and birth anomalies. Appropriate management of asthma has shown to mitigate many of these adverse outcomes. This review aims to give clinicians a general overview on the epidemiology, management and safety of asthma treatment during pregnancy. METHODS: We performed a narrative literature review to offer a broad perspective of the most relevant aspects of asthma during pregnancy. RESULTS: Evidence shows that the risks of guideline-based asthma treatment are lower than the risks and outcomes associated with poorly controlled asthma, especially in regards to malformations. Asthma is not a contraindication to pregnancy and likewise most currently available treatments are not contraindicated in pregnancy. A multidisciplinary approach is the ideal strategy, with a special emphasis on increasing adherence, which will be associated with better outcomes for both the mother and baby. CONCLUSION: Asthma management during pregnancy follows the same principles as that of in the non-pregnant asthma subject but there needs to be a strong emphasis on achieving good adherence.
Asthma in pregnancy: a review of recent literature

Kelly Colas,Jennifer Namazy

DOI: https://doi.org/10.1097/mcp.0000000000001072

IF: 3.3

2024-03-22

Current Opinion in Pulmonary Medicine

Abstract:Purpose of review Asthma remains the most common respiratory disease in pregnancy. Identifying risk factors for asthma exacerbations during pregnancy is critical, as uncontrolled asthma can have detrimental effects for both mother and baby. In this review, we discuss recent literature exploring risk factors, fetal and maternal effects, and treatment options for asthma during pregnancy. Recent findings Recent literature suggests that optimizing asthma during pregnancy improves outcomes for both mother and baby, as well as later in childhood. Current research affirms that the benefit of asthma medication use outweighs any potential risks related to the medications themselves. Limited information is available regarding the use of newer therapies such as biologics during pregnancy. Summary Identifying risk factors for asthma exacerbations during pregnancy is critical to prevent adverse outcomes for both mother and baby. Recent evidence continues to affirm the safety of asthma medication use; more studies are needed regarding the use of new therapies during pregnancy.

respiratory system
Obstetric Management of High-Risk Asthmatic, Allergic Patients and Anaphylaxis

Mitchell Dombrowski

DOI: https://doi.org/10.1007/978-3-030-03395-8_12

2018-12-30

Abstract:In general, data are lacking to guide the optimal obstetric management of asthma, and recommendations are based on extrapolation of data from other clinical settings and expert opinion. Gravida should be offered influenza vaccination as appropriate. Those with persistent asthma are at risk for pregnancy complications and may benefit from increased fetal surveillance, including fetal nonstress testing and estimation of fetal growth by ultrasound. Adverse outcomes may be more common if asthma severity is underestimated and the asthma undertreated. Stopping asthma medications in the first trimester can cause exacerbations resulting in an increased risk of fetal malformations. It is safer for pregnant women to be treated with asthma medications than it is for them to have asthma symptoms and exacerbations. Identifying and controlling or avoiding triggering factors such as allergens and irritants, particularly tobacco smoke, can lead to improved maternal well-being with less need for medication. The goal of asthma therapy is maintenance of near normal pulmonary function. Women with significant allergic disease should be evaluated prior to pregnancy, so that skin testing, challenge procedures, or other exposures that might be necessary for definitive diagnosis can be safely performed. A plan for management during pregnancy can then be formulated. Anaphylaxis is a rare but potentially deadly complication for both mother and baby. The prognosis is dependent upon early diagnosis and rapid medical management. Cesarean delivery can be life-saving for the fetus and may enhance maternal survival. In the case of perimortem anaphylaxis, fetal outcome is optimized if emergent cesarean delivery can be accomplished within 5 min and can also increase maternal survival due to reduced aortocaval compression by the uterus and increased maternal cardiac output. Anaphylaxis remote from term can cause difficult management and ethical decisions regarding early delivery.
Impact of Asthma Medications During Pregnancy on Asthma Exacerbation, Maternal, and Neonatal Outcomes

Sangmin Lee,Erin Hetherington,Richard Leigh,Kaylee Ramage,Amy Metcalfe

DOI: https://doi.org/10.1016/j.jaip.2024.02.017

Abstract:Background: Asthma affects 5% to 13% of pregnant women, and many require daily pharmacotherapy to achieve asthma control; however, adherence to medication during pregnancy often decreases. Objective: To understand the association between the use of or adherence to asthma medication with asthma exacerbation and maternal/neonatal outcomes. Methods: Using linked population-based administrative databases from Alberta, Canada (2012-2018), pregnant women with asthma were categorized based on asthma medication use 1 year before pregnancy: short-acting β-agonists (SABA), inhaled corticosteroids (ICS), and ICS with long-acting β-agonists (ICS+LABA). Women on ICS+LABA were grouped by trajectory of adherence during pregnancy using group-based trajectory modeling. Logistic regressions were used to estimate the associations between the use of or trajectories of adherence to asthma medication during pregnancy with asthma exacerbation and maternal/neonatal outcomes. Results: Overall, 13,509 of 238,751 (5.7%) pregnant women had asthma before pregnancy (SABA: 24.7%; ICS: 12.5%; ICS+LABA: 25.1%; none: 36.1%). The use of SABA (adjusted odds ratio [aOR]: 1.79, 95% confidence interval [CI]: 1.21, 2.64), ICS (aOR: 3.37, 95% CI: 2.10, 5.39), and ICS+LABA (aOR: 3.64, 95% CI: 2.57, 5.17) had greater odds of disease exacerbation than no asthma medication during pregnancy. ICS+LABA adherence groups during pregnancy included low (79.8%), moderate-to-decreasing (14.0%), and moderate-to-increasing (6.2%). The moderate-to-decreasing (aOR: 1.45, 95% CI: 1.14, 1.84) and moderate-to-increasing (aOR: 2.06, 95% CI: 1.50, 2.83) adherence groups had greater odds of disease exacerbation than the low adherence group. ICS use during pregnancy decreased odds of preterm birth (aOR: 0.62; 95% CI: 0.39, 0.99) and neonatal intensive care unit admission (aOR: 0.66; 95% CI: 0.45, 0.97). Other group comparisons were not statistically significant. Conclusions: Our study shows the importance of continuing asthma maintenance medication during pregnancy to improve outcomes. Future research should study the postpartum and long-term outcomes with asthma medication during pregnancy.
Design and synthesis of an array of selective androgen receptor modulators.

R. Trump,Jean-Baptiste E Blanc,E. Stewart,P. Brown,M. Caivano,D. W. Gray,W. Hoekstra,T. Willson,B. Han,P. Turnbull

DOI: https://doi.org/10.1021/CC060096E

Journal of Combinatorial Chemistry

Abstract:We describe the design, using shape comparison and fast docking computer algorithms, and rapid parallel synthesis of a 1300 member array based on GSK7721, a 4-aminobenzonitrile androgen receptor (AR) antagonist identified by focused screening of the GSK compound collection. The array yielded 352 submicromolar and 17 subnanomolar AR agonists as measured by a cell-based reporter gene functional assay. The rapid synthesis of a large number of active compounds provided valuable information in the optimization of AR modulators, which may be useful in treating androgen deficiency in aging males.
Influence of pregnancy on asthma exacerbation patterns: a UK population-based cohort

Valencia-Hernandez,C.,Wong,E.,Bloom,C.

DOI: https://doi.org/10.1183/13993003.congress-2024.oa5577

IF: 24.3

2024-11-01

European Respiratory Journal

Abstract:Background: GINA notes that during pregnancy, about one-third of women have worsening asthma symptoms, one-third improve, and one-third remain unchanged. This data is from a US cohort of 330 women from the 1980s. We wished to understand current exacerbation patterns. Methods: Using UK medical records, 2004-2019, we drew an asthma cohort with data: 1-year pre-pregnancy, during all 3 pregnancy trimesters, and 1-year post-pregnancy. We defined exacerbations as a short course of oral steroids or unplanned hospital visit. We calculated the proportion having ≥1 exacerbation in each 3-month period. Results: We included 72,791 pregnancies (mean age=31 years; mean pregnancy length=39 weeks). By asthma therapy in the year pre-pregnancy, 50% only used a reliever, 19% low-dose inhaled corticosteroids (ICS), 16% infrequent medium/high-dose ICS, 11% regular medium-dose ICS and 5% regular high-dose ICS. Overall, hospital-managed exacerbations rose in the second and third trimester. But primary care-managed exacerbations fell in all three trimesters (figure). All exacerbations were lower 3-months post-pregnancy. Conclusion: During pregnancy, there were relatively fewer primary care-managed exacerbations, especially if using higher doses of ICS, but more hospital and A&E admissions. All exacerbations fell 3-months post-pregnancy. By 12-months post-pregnancy, women using the highest ICS doses still had lower exacerbation rates than pre-pregnancy.

respiratory system
Treatable Traits in Pregnant Women with Asthma

Meera Ramlal,Renske Van der Meer,Sarah Bendien

DOI: https://doi.org/10.1159/000536455

2024-01-01

Respiration

Abstract:Background: Asthma is the most common chronic respiratory disease in pregnancy, affecting approximately 8–10% of pregnant women. Uncontrolled asthma is associated with adverse perinatal outcomes, including low birth weight, preterm birth, and maternal complications such as pre-eclampsia. Summary: A current approach to the management of chronic airway diseases is based on targeting treatable traits. The aim of this review was to define treatable traits in pregnant women with asthma based on recent literature and to determine personalized treatment options according to these traits. Traits addressed in this review that may improve asthma control and pregnancy outcomes are fractional exhaled nitric oxide-based asthma monitoring and treatment, medication adherence and inhalation technique, impaired lung function, smoking cessation and comorbidity including psychological conditions (depression and anxiety), obesity, rhinitis, gastroesophageal reflux disease, chronic rhinosinusitis with or without nasal polyps, and sleep apnea. Key Messages: All the treatable traits discussed have the potential to improve asthma control and pregnancy outcomes in pregnant women with asthma. Further research is needed to determine which management approaches are best to improve asthma control during pregnancy, to identify other relevant treatable traits, and to determine whether the treatable trait approach is feasible and beneficial in pregnant women with asthma.

respiratory system
Factors affecting asthma control in pregnancy: A cross-sectional study

Kaleem Ullah Toori,Muhammad Arsalan Qureshi

DOI: https://doi.org/10.12669/pjms.40.6.8659

2024-05-23

Pakistan Journal of Medical Sciences

Abstract:Background and Objective: Asthma control in pregnant women remains of utmost importance; suboptimal control can have adverse repercussions on both fetal and maternal health. The objective was to identify the factors that affect asthma control in pregnant Pakistani women presenting to a tertiary care hospital. Methods: This descriptive, cross-sectional research was conducted at KRL General Hospital between 1st November 2022 to 30th April 2023. Non-probability technique was used to sample one hundred and forty-five pregnant women with confirmed bronchial asthma irrespective of their trimester presented. Data regarding demographics and factors affecting asthma control was collected. Results: The mean age was 30.39 ± 4.33 years, with two-thirds (65%) being multiparous. Approximately 48% of participants were non-compliant with treatment, and less than 40% achieved adequate asthma control. A chi-squared test applied showed that multiparity (p = 0.003), treatment compliance (p < 0.001), BMI (p < 0.001), and proper inhaler technique (p < 0.001) were statistically significant factors affecting asthma control in pregnant women while, the level of education and household income did not exhibit a significant association. Multiple regression analysis qualified higher BMI, multiparity, treatment compliance, and inhaler technique as significant predictors of asthma control amongst pregnant women. Conclusion: Ensuring asthma control during pregnancy is important. This study identified BMI, multiparity, inhaler technique, and treatment compliance as factors that affect asthma control in pregnant women. Addressing these factors through regular antenatal check-ups can significantly mitigate risks and promote the optimal health of both maternal and fetal lives. doi: https://doi.org/10.12669/pjms.40.6.8659 How to cite this: Toori KU, Qureshi MA. Factors affecting asthma control in pregnancy: A cross-sectional study. Pak J Med Sci. 2024;40(6):1146-1150. doi: https://doi.org/10.12669/pjms.40.6.8659 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

medicine, general & internal
Telehealth to improve asthma control in pregnancy: A randomized controlled trial

Elida Zairina,Michael J Abramson,Christine F McDonald,Jonathan Li,Thanuja Dharmasiri,Kay Stewart,Susan P Walker,Eldho Paul,Johnson George

DOI: https://doi.org/10.1111/resp.12773

IF: 6.9

Respirology

Abstract:Background and objective: Poorly controlled asthma during pregnancy is hazardous for both mother and foetus. Better asthma control may be achieved if patients are involved in regular self-monitoring of symptoms and self-management according to a written asthma action plan. Telehealth applications to optimize asthma management and outcomes in pregnant women have not yet been evaluated. This study evaluated the efficacy of a telehealth programme supported by a handheld respiratory device in improving asthma control during pregnancy. Methods: Pregnant women with asthma (n = 72) from two antenatal clinics in Melbourne, Australia, were randomized to one of two groups: (i) intervention-involving a telehealth programme (management of asthma with supportive telehealth of respiratory function in pregnancy (MASTERY(©) )) supported by a handheld respiratory device and an Android smart phone application (Breathe-easy(©) ) and written asthma action plan or (ii) control-usual care. The primary outcome was change in asthma control at 3 and 6 months (prenatal). Secondary outcomes included changes in quality of life and lung function, and perinatal/neonatal outcomes. Results: At baseline, participants' mean (± standard deviation) age was 31.4 ± 4.5 years and gestational age 16.7 ± 3.1 weeks. At 6 months, the MASTERY group had better asthma control (P = 0.02) and asthma-related quality of life (P = 0.002) compared with usual care. There were no significant differences between groups in lung function, unscheduled health-care visits, days off work/study, oral corticosteroid use, or perinatal outcomes. Differences between groups were not significant at 3 months. Conclusion: Telehealth interventions supporting self-management are feasible and could potentially improve asthma control and asthma-related quality of life during pregnancy.
Factors affecting asthma control in pregnant women with asthma.

Toori,K.,Qureshi,M. A.

DOI: https://doi.org/10.1183/13993003.congress-2024.pa4773

IF: 24.3

2024-11-01

European Respiratory Journal

Abstract:Background: Asthma control in pregnant women is imperative as suboptimal control can have adverse repercussions on both fetal and naternal health. Objective: To identify factors that affect asthma control in pregnant women in local Pakistani population. Methods: Descriptive, cross-sectional study of 145 pregnant women with confirmed bronchial asthma. Results: Mean age was 30.39 ± 4.33 years with 65% being multiparous. 48% were non-compliant with treatment and less than 40% achieved asthma control. A chi-squared test applied showed that multiparity (p=0.003, treatment compliance (p<0.001), higher BMI (p<0.001), and proper inhaler technique (p<0.001) were statistically significant factors affecting affecting control in pregnant women while level of education and socioeconomic status did not exhibit any significant association. Multiple regression analysis qualified higher BMI, multiparity, treatment compliance, and inhaler technique as significant predictors of asthma control amongst pregnant women. Conclusion: Ensuring asthma control during pregnancy is important. High BMI, multiparity, correct inhaler technique and treatment compliance affect asthma control. Addressing these factors through regular ante-natal check-ups can significantly improve maternal and featal health.

respiratory system
Non-allergic factors that influence asthma control in pregnancy

Agnieszka Rey,Marta Chełmińska,Iwona Damps-Konstańska

DOI: https://doi.org/10.18332/ejm/191295

2024-08-28

Abstract:Introduction: Numerous factors may influence the asthma course during pregnancy, potentially elevating the risk of specific pregnancy complications. This study aimed to evaluate non-allergic factors influencing asthma and to assess perinatal outcomes between asthmatic and non-asthmatic pregnancies in the population of the Pomeranian Voivodeship region of Poland. Methods: The mixed cohort study was performed with 83 pregnant asthmatic patients aged 18-38 years. The control group consisted of 83 patients without asthma diagnosis or symptoms. A specially designed questionnaire was used to evaluate asthma course and perinatal outcomes. An Asthma Control Test (ACT) adapted for pregnancy was performed on enrollment. Asthma severity was assessed according to GINA guidelines. Results: In 19 cases (22.80%), patients quit their regular treatment after pregnancy was confirmed. Respiratory tract infection occurred in 23 patients (27.71%) and had been statistically significantly more frequent among patients with partially and uncontrolled asthma (χ2=8.504, p<0.05). No statistically significant difference was found between infection episodes and perinatal complications. The incidence of cesarean section was significantly higher among patients with asthma (χ2=16.37, p<0.01), particularly in patients with severe asthma (χ2=7.07, p<0.05) and uncontrolled asthma (χ2=6.7, p<0.05). Apgar score was statistically significantly lower in patients with severe asthma (χ2=20.37, p<0.05). Conclusions: Respiratory tract infections and adequate asthma treatment are the most important modifiable factors in preventing perinatal complications associated with asthma.
Asthma knowledge, care, and outcome during pregnancy: The QAKCOP study

Wanis H Ibrahim,Fatima Rasul,Mushtaq Ahmad,Abeer S Bajwa,Laith I Alamlih,Anam M El Arabi,Mujahed M Dauleh,Ibrahim Y Abubeker,Muhammed U Khan,Tayseer S Ibrahim,Azdin A Ibrahim

DOI: https://doi.org/10.1177/1479972318767719

Abstract:Asthma is the most common chronic medical condition affecting pregnancy. Optimizing asthma management in pregnancy is paramount for the well-being of both the mother and the baby. The primary objectives of this study were to assess patient's knowledge about asthma, the level of asthma care, and fetal and maternal outcomes among pregnant asthmatic women in this wealthy country with tremendous improvement in maternal and fetal health care. The secondary objective was to identify barriers to asthma control. This was a cross-sectional, face-to-face, prospective study of 80 pregnant women with physician-diagnosed asthma. About 56% of patients reported worsening of their asthma control during pregnancy, of which 52.3% felt this worsening in the third trimester. About 65% of patients had uncontrolled asthma during their pregnancy, and inhaler technique was incorrect in 64.4%. Only 38% of patients knew the difference between controller and reliever asthma medications, 12.7% of patients had received written asthma action plan, 17% had a spirometry done in the previous 5 years, and 3.8% had peak expiratory flow meter at home. The main reasons for uncontrolled asthma were lack of knowledge about right asthma medications in 30% and fear of side effects of inhaled corticosteroids in 19% of patients. No financial reason was reported. Significant associations between total number of pregnancies, poor perception of asthma medications, asthma exacerbation during delivery and poor asthma control were observed. Preeclampsia and congenital anomalies occurred at higher rates than previously reported among general population in this country. The tremendous improvements in maternal health care and socioeconomic status do not seem to be a barrier to the globally recognized poor asthma care in pregnancy. Important strategies are much needed.
Diagnosis and Treatment of Asthma in Nonpregnant Women

Jana Esden,Nancy Pesta-Walsh

DOI: https://doi.org/10.1111/jmwh.12907

Abstract:Asthma is a common condition affecting 8.3% of the adult population in the United States. The disease is characterized by chronic airway inflammation that leads to airway hyperresponsiveness and obstruction that results in coughing, wheezing, shortness of breath, and a feeling of chest tightness. The diagnosis and classification of asthma is based on reported symptoms, physical examination findings, and spirometry. Pharmacologic therapy is prescribed using a stepwise approach that begins with inhaled short-acting beta2 -agonists for intermittent asthma with the addition of daily inhaled corticosteroids for more persistent cases. Individuals with asthma are reevaluated on a regular basis to monitor symptoms, and pharmacologic treatments are adjusted as needed. Familiarity with the stepwise approach for asthma management and confidence in the efficacy and safety profiles of inhaled medications will assist clinicians in successful management of asthma in the primary care setting.
Management of patients with allergic diseases during pregnancy: lecture

S.V. Zaikov,A.Ye. Bogomolov,N.A. Hritsova,A.P. Grуshуlo

DOI: https://doi.org/10.32902/2663-0338-2022-3-42-53

2022-10-24

Infusion & Chemotherapy

Abstract:ABSTRACT. In connection with the considerable increase of prevalence of allergic diseases (AD) there all more often are situations, when it will be to decide the question of management of patients a doctor with an allergy during pregnancy. Prevalence of AD (allergic rhinitis/conjunctivitis, allergic phenotypes of bronchial asthma and hives, atopic dermatitis, food/drug/insect allergy, anaphylaxis) among pregnant women can arrive 30 %. It is possible to distinguish three types of influence of pregnancy on clinical motion of AD: 1) presence of pregnancy does not affect motion of AD; 2) on a background pregnancy comes remission of AD; 3) on a background pregnancy arise up intensifying of AD and their motion are burdened. It is difficult to predict exactly how the course of AD will occur during pregnancy, while the nature of treatment of a pregnant woman with AD and the level of their control are extremely important. At pregnancy diagnosis of AD is based on data of allergic anamnesis, food diary, physical inspection. Thus realization of skin and provocative tests with allergens contra-indicated. Application of provocative tests is also forbidden with a histamine, а methacholine and an acetylcholine. At treatment of pregnant from AD must be taken into account possible side effects of antiallergic drugs. Setting of modern medicinal facilities allows in most cases to control motion of allergic pathology for pregnant and avoid development of side effects of drugs. Treatment of AD during pregnancy the best result must provide for a mother and child. Medical workers must inform the women of reproductive age and pregnant of potential risks and present/absent proofs of unconcern/ununconcern of diagnostic and curative events.
Obstetric complications in the 3rd trimester of pregnancy in women with asthma

A.A. Pashchenko,,Yu.E. Dobrokhotova,D.S. Fomina,,,,

DOI: https://doi.org/10.32364/2618-8430-2024-7-2-2

2024-01-01

Russian Journal of Woman and Child Health

Abstract:Aim: to analyze the rate of asthma-associated obstetric complications in the third trimester of pregnancy, with attention to the severity and level of symptom control Patients and Methods: a retrospective phase involved the analysis of the course of the third trimester of pregnancy in 120 women with asthma. The women were divided into five groups: mild intermittent asthma (n=34), mild persistent controlled asthma (n=40), mild persistent poorly controlled asthma (n=10), moderate to severe persistent controlled asthma (n=26), and moderate to severe persistent poorly controlled asthma (n=10). The prospective phase included examination and treatment of pregnant women in the groups with uncontrolled asthma (n=20). The level of symptom control was assessed using the Asthma Control Test (ACT). Additionally, nitric oxide in exhaled air (NOex) was measured. The control group included 20 women without allergic disorders. Results: the study demonstrated an association between the level of symptom control and the development of associated hypertensive disorders. Severe preeclampsia was reported only in moderate to severe poorly controlled asthma. A significant correlation was revealed between ACT, NOex level, and de novo increase in systolic blood pressure (BP) in the third trimester (Rs=0.581; Rs=0.828). C-section was most often performed for fetal indications (acute hypoxia) in women with moderate to severe persistent poorly controlled asthma. These findings indicate that the choice of delivery method should be based on the level of symptom control at the end of the third trimester, rather than disease severity. Achieving complete control of asthma in pregnant women reduces the risk of acute fetal hypoxia and the rate of emergency C-sections. Conclusions: achieving and maintaining complete asthma control during pregnancy reduces the risk of associated obstetric complications and improves perinatal and maternal outcomes KEYWORDS: asthma, pregnancy, obstetric complications, hypertension, asthma-associated obstetric complications, C-section. FOR CITATION: Pashchenko A.A., Dobrokhotova Yu.E., Fomina D.S. Obstetric complications in the 3rd trimester of pregnancy in women with asthma. Russian Journal of Woman and Child Health. 2024;7(2):98–103 (in Russ.). DOI: 10.32364/2618-8430-2024-7-2-2.
Asthma and reproductive outcomes: A Danish nationwide cohort study

Vejen Hansen,A.,Hakansson,K. E. J.,Mikkelsen,A. P.,Ali,Z.,Pinborg,A.,Lidegaard,O.,Ulrik,C. S.

DOI: https://doi.org/10.1183/13993003.congress-2024.oa5579

IF: 24.3

2024-11-01

European Respiratory Journal

Abstract:Background: Asthma is common among women of reproductive age. Prior studies revealed associations between asthma and fertility by reporting prolonged time to pregnancy and altered fecundability. Aim: Investigate fertility in women treated with anti-asthmatic drugs (ICS/LABA/LAMA/SABA/LTRA) compared to non-asthmatic controls. Method: All Danish women born 1976 to 1999 were followed from 1994 to 2017. Asthma was identified by repeated redemption of anti-asthmatic drugs with severity per 2018 GINA guidelines. Outcome were fertility treatment, compared to controls applying a Cox regression model adjusted for age, calendar year, and education. Results: In total, 769,880 were included and followed (median time of 10.8 years [IQR 5.3-17.5]). The proportion who gave birth in follow-up was 77%, irrespective of asthma exposure. However, women with asthma experienced higher degree of fetal loss (17.0% vs. 15.7%) and more use of fertility treatment (5.6% vs. 5.0%) compared to controls. Risk of fertility treatment was significantly higher in women with asthma: HR 1.12(1.08-1.15). GINA step 4-5 had the highest risk of needing fertility treatment: HR 1.62(1.43-1.83) and women with ≥ 3 prior exacerbations had an increased risk of needing fertility treatment: HR 1.38(1.19-1.60). Conclusion: Although women with asthma more often require fertility treatment, a risk correlated to asthma severity and exacerbations, asthma does not seem to affect the number of live births.

respiratory system
Asthma exacerbations and inhaled corticosteroid use in pregnancy and child asthma

Brew Haasdyk,B.,Murphy,V.,Gong,T.,Zoega,H.,Havard,A.,Robijn,A.,Smew,A.,Rejno,G.,Lundholm,C.,Almqvist,C.

DOI: https://doi.org/10.1183/13993003.congress-2024.pa4928

IF: 24.3

2024-11-01

European Respiratory Journal

Abstract:Background: Among pregnant women with asthma, maternal exacerbations increase the risk of child asthma whilst taking inhaled corticosteroids (ICS) during pregnancy may decrease the risk. We used two population-wide register-based cohorts with family designs to assess these relationships. Methods: Study populations- mothers with asthma and children born: 1) 2014-2018 in New South Wales (NSW), Australia (n= 34 404), 2) 2008-2021 in Sweden (n = 97 986). ICS during pregnancy was measured as a dispensing in national medication registers. Exacerbation was defined as either an unplanned hospital visit for asthma, ≥ 5 short acting beta agonist or ≥1 oral corticosteroid dispensings. Child asthma was defined as a hospital diagnosis and/or ≥2 asthma medications. Hazard ratios were estimated using cox survival regression. Paternal exposures during the pregnancy and sibling analyses assessed unmeasured confounding. Results: Incidence rates for child asthma were 36 and 42 per 1000 person-years in NSW and Sweden respectively. In both populations the risk of child asthma was higher with an exacerbation in pregnancy (aHR 1.83 95%CI 1.62, 2.08 NSW, aHR 1.42 95%CI 1.36, 1.47 SWE) or ICS in pregnancy (aHR 1.39 95%CI 1.26, 1.54 NSW, aHR 1.29 95%CI 1.25, 1.33 SWE), adjusted for exacerbations. After adjusting for asthma severity the association with maternal exacerbations remained (aHR 1.27 95%CI 1.21, 1.34 SWE) and the association with ICS diminished (aHR 1.07 95%CI 1.03, 1.11 SWE). Paternal, sibling analyses confirmed these findings. Conclusion: Asthma exacerbations in pregnancy increase the risk of child asthma whereas ICS use in pregnancy is not associated with child asthma.

respiratory system
It is time to change the way we manage mild asthma: an update in GINA 2019

Jaya Muneswarao,Mohamed Azmi Hassali,Baharudin Ibrahim,Bandana Saini,Irfhan Ali Hyder Ali,Ashutosh Kumar Verma

DOI: https://doi.org/10.1186/s12931-019-1159-y

2019-08-14

Abstract:Asthma is a heterogeneous lung disease, usually characterised by chronic airway inflammation. Although evidence-based treatments are available in most countries, asthma control remains suboptimal, and asthma-related deaths continue to be an ongoing concern. Generally, it is believed that between 50 to 75% of patients with asthma can be considered as having mild asthma.Previous versions of Global Initiative for Asthma (GINA) suggested that mild asthma in adults can be well managed with either reliever medications, for example, short-acting beta2 agonists (SABA) alone or with the additional use of controllers such as regular low-dose inhaled corticosteroids (ICS). Given the low frequency or non-bothersome nature of symptoms in mild asthma, patients' adherence towards their controller medications, especially to ICS is usually not satisfactory. Such patients often rely on SABA alone to relieve symptoms, which may contribute to SABA over-reliance. Overuse of relievers such as SABAs has been associated with poor asthma outcomes, such as exacerbations and even deaths. The new GINA 2019 asthma treatment recommendations represent significant shifts in asthma management at Steps 1 and 2 of the 5 treatment steps. The report acknowledges an emerging body of evidence suggesting the non-safety of SABAs overuse in the absence of concomitant controller medications, therefore does not support SABA-only therapy in mild asthma and has included new off-label recommendations such as symptom-driven (as-needed) low dose ICS-formoterol and "low dose ICS taken whenever SABA is taken".The GINA 2019 report highlights significant updates in mild asthma management and these recommendations represent a clear deviation from decades of clinical practice mandating the use of symptom-driven SABA treatment alone in those with mild asthma. While the new inclusions of strategies such as symptom-driven (as-needed) ICS-formoterol and "ICS taken whenever SABA is taken" are based on several key trials, data in this context are still only emergent data, with clear superiority of as needed ICS-formoterol combinations over maintenance ICS regimens yet to be established for valid endpoints. Nevertheless, current and emerging data position the clinical asthma realm at a watershed moment with imminent changes for the way we manage mild asthma likely in going forward.
[Transcription and RNA processing of SV40 DNA (author's transl)].

H. Handa

Seikagaku. The Journal of Japanese Biochemical Society

Abstract:
Development of nerves containing nitric oxide synthase in the human male urogenital organs.

J. Dixon,P. Jen

DOI: https://doi.org/10.1111/J.1464-410X.1995.TB00763.X

1995-12-01

British Journal of Urology

Abstract:OBJECTIVE To determine the spatial and temporal distribution of nitric oxide synthase (NOS) in the urogenital organs of a series of human male fetuses, using an immunohistochemical technique. MATERIAL AND METHODS Thirteen pre-natal specimens ranging in gestational age from 13 to 30 weeks were acquired following abortion or miscarriage. The distribution of NOS, which catalyses the production of nitric oxide (NO), was revealed using an indirect immunolabelling technique and compared with the overall innervation of each specimen visualized using the general nerve-marker protein gene product 9.5 (PGP). RESULTS At 13 weeks of gestation the majority of nerves supplying the developing prostate gland expressed NOS while similar nerves formed a very minor proportion of the total innervation to the urinary bladder and intramural ureters. With increasing gestational age, NOS-containing nerves became more numerous in the lower urinary tract, the majority occurring at the bladder neck and around the prostatic urethra. In contrast, NOS-containing nerves were not detected in the muscle coat of the vas deferens and seminal vesicle until 23 weeks of gestation and at 30 weeks still only formed a small proportion of the intramuscular nerves. From 23 weeks onwards NOS-containing nerves were present occasionally in the dense subepithelial nerve plexuses which developed in the bladder, prostate, vas deferens and seminal vesicle. Also from 23 weeks onwards, many of the epithelial cells lining the vas deferens, seminal vesicle and ejaculatory ducts showed immunoreactivity to NOS but no immunoreactivity was observed in the epithelial lining of the urinary bladder and the intramural ureters. CONCLUSION Based on the comparative density of NOS-containing nerves and the difference in their temporal development among the various urogenital organs it is apparent that NO plays an increasingly important role in the autonomic control of the lower urinary tract during fetal development but that its involvement in the functional control of the vas deferens and seminal vesicle is relatively minor before birth.

Surface absorption in KCI and CaF(2) at 2.8 microm and 3.8 microm.

Asthma and pregnancy: A review of management strategies with an emphasis on medication safety and outcomes

Asthma in pregnancy: a review of recent literature

Obstetric Management of High-Risk Asthmatic, Allergic Patients and Anaphylaxis

Impact of Asthma Medications During Pregnancy on Asthma Exacerbation, Maternal, and Neonatal Outcomes

Design and synthesis of an array of selective androgen receptor modulators.

Influence of pregnancy on asthma exacerbation patterns: a UK population-based cohort

Treatable Traits in Pregnant Women with Asthma

Factors affecting asthma control in pregnancy: A cross-sectional study

Telehealth to improve asthma control in pregnancy: A randomized controlled trial

Factors affecting asthma control in pregnant women with asthma.

Non-allergic factors that influence asthma control in pregnancy

Asthma knowledge, care, and outcome during pregnancy: The QAKCOP study

Diagnosis and Treatment of Asthma in Nonpregnant Women

Management of patients with allergic diseases during pregnancy: lecture

Obstetric complications in the 3rd trimester of pregnancy in women with asthma

Asthma and reproductive outcomes: A Danish nationwide cohort study

Asthma exacerbations and inhaled corticosteroid use in pregnancy and child asthma

It is time to change the way we manage mild asthma: an update in GINA 2019

[Transcription and RNA processing of SV40 DNA (author's transl)].

Development of nerves containing nitric oxide synthase in the human male urogenital organs.